Clinical Trials · NCT00382174
Study of Thymosin Beta 4 in Patients With Pressure Ulcers
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- RegeneRx Biopharmaceuticals, Inc.
- Enrollment
- 72
- Start date
- May 2006
- Locations
- 12 sites, United States
- Primary endpoint
- Safety and Tolerability of Thymosin Beta 4 (Tβ4)Applied for up to 84 Days